Cycling B-CLL cells are highly susceptible to inhibition of the proteasome: involvement of p27, early D-type cyclins, Bax, and caspase-dependent and -independent pathways
- PMID: 12644019
- DOI: 10.1016/s0301-472x(02)01076-7
Cycling B-CLL cells are highly susceptible to inhibition of the proteasome: involvement of p27, early D-type cyclins, Bax, and caspase-dependent and -independent pathways
Abstract
Objective: Although peripheral blood B-CLL cells are arrested in G0 phase of the cell cycle, a proliferating pool of cells in proliferation centers might be involved in disease progression. We have previously described an in vitro model of this proliferating pool of cells using B-CLL cells stimulated with immunostimulatory oligonucleotides (CpG-ODN) and interleukin-2. Lactacystin is a specific inhibitor of the proteasome and is a potent apoptosis inductor in resting peripheral B-CLL cells. In the present study, we investigated the effect of proteasome inhibition in proliferating B-CLL cells.
Methods: The effect of proteasome inhibition was analyzed using thymidine incorporation, annexin V assays, and TUNEL staining. Immunoblots were performed to evaluate expression of proteins involved in cell cycle and apoptosis regulation.
Results: Lactacystin blocked cell cycle progression in activated B-CLL cells and inhibited degradation of p27. Upregulation of cyclin D2 and D3 in activated B-CLL cells was inhibited while the expression of cdk2, cdk4, and cyclin E remained unchanged. Activated B-CLL cells were more susceptible to apoptosis induction as compared to resting B-CLL cells. Apoptosis induction was accompanied by cleavage of Bax, procaspase 8, procaspase 9, and procaspase 3. However, a broad-spectrum caspase inhibitor (z-VAD.fmk) only partially inhibited cell death although DNA degradation was completely inhibited.
Conclusion: Proteasome inhibition is highly effective in proliferating B-CLL cells and induces apoptosis using a caspase-dependent and -independent pathway.
Copyright 2003 International Society for Experimental Hematology
Similar articles
-
Inhibition of proteasome function induced apoptosis in gastric cancer.Int J Cancer. 2001 Aug 15;93(4):481-8. doi: 10.1002/ijc.1373. Int J Cancer. 2001. PMID: 11477551
-
p27Kip1 accumulation by inhibition of proteasome function induces apoptosis in oral squamous cell carcinoma cells.Clin Cancer Res. 2000 Mar;6(3):916-23. Clin Cancer Res. 2000. PMID: 10741716
-
Role of proteasomes in T cell activation and proliferation.J Immunol. 1998 Jan 15;160(2):788-801. J Immunol. 1998. PMID: 9551914
-
Ubiquitin-proteasome system and increased sensitivity of B-CLL lymphocytes to apoptotic death activation.Leuk Lymphoma. 2000 Aug;38(5-6):499-504. doi: 10.3109/10428190009059268. Leuk Lymphoma. 2000. PMID: 10953970 Review.
-
Lactacystin, proteasome function, and cell fate.J Biol Chem. 1998 Apr 10;273(15):8545-8. doi: 10.1074/jbc.273.15.8545. J Biol Chem. 1998. PMID: 9535824 Review. No abstract available.
Cited by
-
CTLA-4 affects expression of key cell cycle regulators of G0/G1 phase in neoplastic lymphocytes from patients with chronic lymphocytic leukaemia.Clin Exp Med. 2016 Aug;16(3):317-32. doi: 10.1007/s10238-015-0360-7. Epub 2015 May 24. Clin Exp Med. 2016. PMID: 26003188 Free PMC article.
-
Methylmercury elicits rapid inhibition of cell proliferation in the developing brain and decreases cell cycle regulator, cyclin E.Neurotoxicology. 2006 Dec;27(6):970-81. doi: 10.1016/j.neuro.2006.09.001. Epub 2006 Sep 15. Neurotoxicology. 2006. PMID: 17056119 Free PMC article.
-
Targeting the UPS as therapy in multiple myeloma.BMC Biochem. 2008 Oct 21;9 Suppl 1(Suppl 1):S1. doi: 10.1186/1471-2091-9-S1-S1. BMC Biochem. 2008. PMID: 19007431 Free PMC article. Review.
-
Is targeted chemotherapy an alternative to immunotherapy in chronic lymphocytic leukemia?Cancer Immunol Immunother. 2006 Feb;55(2):221-8. doi: 10.1007/s00262-005-0032-7. Epub 2005 Jul 21. Cancer Immunol Immunother. 2006. PMID: 16034559 Free PMC article. Review.
-
Analysis of CD23 antigen expression in B-chronic lymphocytic leukaemia and its correlation with clinical parameters.Med Oncol. 2008;25(3):315-22. doi: 10.1007/s12032-007-9038-7. Epub 2008 Jan 9. Med Oncol. 2008. PMID: 18183502
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials